This program is intended for research-driven academic and translational teams working at the intersection of drug delivery, molecular interactions, and safety assessment, including both academic institutions and select early-stage biotech organizations.

Eligible Applicants

Applications are welcome from the following groups worldwide:

Academic & Non-Profit Researchers

• Principal Investigators (PIs) at universities or academic medical centers
• Postdoctoral researchers applying with PI support
• Senior graduate students with demonstrated research focus and PI endorsement
• Researchers at non-profit research institutes

Research-Focused Small Biotech & Early-Stage Pharma

• Seed to Series B biotech companies
• Translational research teams within small or virtual pharma organizations
• Biotech startups developing preclinical or IND-enabling programs
• Participation from industry is limited to organizations with a clear research and translational mandate. This program is not intended for late-stage commercial product development or contract screening services.

Research Backgrounds Well Suited for This Program

• This opportunity is particularly relevant for teams working in:
• Drug delivery and formulation science
• Pharmacology and PK/PD
• Medicinal chemistry and chemical biology
• Computational chemistry and molecular modeling
• Nanomedicine and biomaterials
• Translational therapeutics and safety biology
• Systems biology and off-target biology
• Polypharmacy and combination therapy research

Both small molecules and delivery-enabled therapeutic platforms (e.g., formulations, conjugates, nanoparticles) are within scope.

Project Characteristics That Are a Good Fit

• Projects well suited for this program typically involve:
• Preclinical candidates with delivery, exposure, or toxicity uncertainty
• Questions around off-target interaction risk
• Comparative evaluation of delivery strategies or formulations
• Mechanistic hypotheses that are difficult to probe experimentally alone
• No prior experience in quantum computing or advanced simulation is required.

What This Program Is Not

To ensure clarity and protect intellectual property, this program is not intended for:

• Contract research or fee-for-service screening
• Method or algorithm development requests
• Access to proprietary solver implementations or source code
• Late-stage commercial optimization programs
• Participants receive interpretable scientific outputs and comparative insights, not implementation-level access.

Ideal Applicant Profile (Summary)

The ideal applicant is a research-oriented academic or biotech team that:

Is working in early to mid-preclinical development

Faces delivery or safety-related uncertainty

Recognizes limitations of conventional docking or screening

Seeks deeper mechanistic insight to guide translational decisions

Sponsor Institute/Organizations: QuanDruPlex Inc

Sponsor Type: Corporate/Non-Profit

Address: Summer Street, Boston, USA

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.